883 related articles for article (PubMed ID: 22768354)
1. Genital warts: a comprehensive review.
Yanofsky VR; Patel RV; Goldenberg G
J Clin Aesthet Dermatol; 2012 Jun; 5(6):25-36. PubMed ID: 22768354
[TBL] [Abstract][Full Text] [Related]
2. Nonavalent human papillomavirus vaccination as alternative treatment for genital warts.
Bossart S; Gabutti MP; Seyed Jafari SM; Hunger RE
Dermatol Ther; 2020 Jul; 33(4):e13771. PubMed ID: 32500585
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of genital human papillomavirus infection in a female adolescent population.
Jamison JH; Kaplan DW; Hamman R; Eagar R; Beach R; Douglas JM
Sex Transm Dis; 1995; 22(4):236-43. PubMed ID: 7482107
[TBL] [Abstract][Full Text] [Related]
4. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
5. An evidence-based review of medical and surgical treatments of genital warts.
Scheinfeld N; Lehman DS
Dermatol Online J; 2006 Mar; 12(3):5. PubMed ID: 16638419
[TBL] [Abstract][Full Text] [Related]
6. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
[TBL] [Abstract][Full Text] [Related]
7. [Proven and new methods in the treatment of genital warts].
Schneede P; Waidelich R
Urologe A; 2013 Oct; 52(10):1416-21. PubMed ID: 24026888
[TBL] [Abstract][Full Text] [Related]
8. Condylomata acuminata (genital warts): patient demographics and treating physicians.
Fleischer AB; Parrish CA; Glenn R; Feldman SR
Sex Transm Dis; 2001 Nov; 28(11):643-7. PubMed ID: 11677386
[TBL] [Abstract][Full Text] [Related]
9. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study.
Hillemanns P; Breugelmans JG; Gieseking F; Bénard S; Lamure E; Littlewood KJ; Petry KU
BMC Infect Dis; 2008 Jun; 8():76. PubMed ID: 18518976
[TBL] [Abstract][Full Text] [Related]
10. Updates on human papillomavirus and genital warts and counseling messages from the 2010 Sexually Transmitted Diseases Treatment Guidelines.
Dunne EF; Friedman A; Datta SD; Markowitz LE; Workowski KA
Clin Infect Dis; 2011 Dec; 53 Suppl 3():S143-52. PubMed ID: 22080267
[TBL] [Abstract][Full Text] [Related]
11. Condylomata acuminata in children: frequent association with human papillomaviruses responsible for cutaneous warts.
Obalek S; Jablonska S; Favre M; Walczak L; Orth G
J Am Acad Dermatol; 1990 Aug; 23(2 Pt 1):205-13. PubMed ID: 2170467
[TBL] [Abstract][Full Text] [Related]
12. Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.
Dahlstrom KR; Fu S; Chan W; Shelal Z; Ramondetta LM; Lairson DR
Pharmacoeconomics; 2018 Nov; 36(11):1355-1365. PubMed ID: 30019118
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and associated costs for genital warts in Italy.
Merito M; Largeron N; Cohet C; Timelli L; Boselli F; Matteelli A; Naldi L; Vittori G
Curr Med Res Opin; 2008 Nov; 24(11):3175-83. PubMed ID: 18851777
[TBL] [Abstract][Full Text] [Related]
14. Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents.
Perkins RB; Lin M; Wallington SF; Hanchate A
Sex Transm Dis; 2017 Jun; 44(6):365-370. PubMed ID: 28499288
[TBL] [Abstract][Full Text] [Related]
15. The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland.
Coles VA; Chapman R; Lanitis T; Carroll SM
Int J STD AIDS; 2016 Jan; 27(1):51-7. PubMed ID: 25681263
[TBL] [Abstract][Full Text] [Related]
16. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
Gilson R; Nugent D; Bennett K; Doré CJ; Murray ML; Meadows J; Haddow LJ; Lacey C; Sandmann F; Jit M; Soldan K; Tetlow M; Caverly E; Nathan M; Copas AJ
Health Technol Assess; 2020 Sep; 24(47):1-86. PubMed ID: 32975189
[TBL] [Abstract][Full Text] [Related]
17. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2013 Aug; 31(37):3899-905. PubMed ID: 23820080
[TBL] [Abstract][Full Text] [Related]
18. The interaction of high and low-risk human papillomavirus genotypes increases the risk of developing genital warts: A population-based cohort study.
Hasanzadeh M; Rejali M; Mehramiz M; Akbari M; Mousavi Seresht L; Yazdandoost Y; Farokhi S; Mahdian Z; Maleki F; Emamdadi-Aliabad Z; Jalilvand N; Khorrami S; Fadaei Z; Movahedi M; Hosseini Z; Razmi F; Takamoli T; Ferns GA; Avan A
J Cell Biochem; 2019 Aug; 120(8):12870-12874. PubMed ID: 30868650
[TBL] [Abstract][Full Text] [Related]
19. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
20. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom.
Woodhall SC; Jit M; Cai C; Ramsey T; Zia S; Crouch S; Birks Y; Newton R; Edmunds WJ; Lacey CJ
Sex Transm Dis; 2009 Aug; 36(8):515-21. PubMed ID: 19543143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
